• 2022/09/02 | ArchiMed Impact Report 2021 - Investing for Better Healthcare: a Global Challenge

    At ArchiMed, we are convinced of the crucial role healthcare companies play in sustaining humanity’s well-being, and we we have witnessed for over 20 years their tremendous contribution.

    We firmly believe that the healthcare industry has all the required characteristics to embody an impact vision: products and services with a greater purpose for human and animal health ; as we also believe that only companies realizing their sustainability potential can endure and create long-term value.

    As an impact investor, we intend to guide healthcare actors towards building resilient and equitable healthcare systems, supporting access to a healthy life. To achieve this mission, we fully integrate sustainability throughout our activities involving all our teams and our portfolio companies.

    To retrieve our ArchiMed Impact Report 2021, please click here

    More
  • 2022/08/08 | ArchiMed reaches agreement to sell healthcare logistics provider Bomi Group to UPS

    The agreed purchase by UPS and previous liquidity events return 70 percent of their money, on a cash-to-cash basis, to MED Platform I’s Investors, just three years after the fund closed in 2019. The confidential terms of the transaction are not being disclosed at this time.

    ArchiMed has reached agreement to sell healthcare logistics provider Bomi Group to UPS (NYSE: UPS), the world’s largest courier and logistics group. Bomi is invested out of ArchiMed’s MED Platform I, which closed on commitments of €1.5 billion in 2020 (€1.0 billion excluding co-investment vehicles), then a record for a Europe-based private equity healthcare fund, about to be beaten by MED Platform II. Following the sale, and previous liquidity events for other portfolio companies, MED Platform I has distributed 70 percent of its invested capital. The fund’s total performance is already at a 2.2 times multiple, or a 69 percent annualized return. This makes MED Platform I a strong top-decile performer for all buyout funds launched in 2019, according to Preqin data, in line with ArchiMed’s smallcap fund MED II for its corresponding 2018 vintage (MED I is the best performing Buyout fund at a global level for the 2014 vintage).

    “In partnership with management and the founding family, we rapidly internationalized Bomi’s exceptional expertise in healthcare logistics and applied it to a wider range of sector services,” says ArchiMed Managing Partner André-Michel Ballester. “We’re delighted that the stewardship of Bomi will now pass to UPS - they are the logical candidate to take this company to the next level.” The sale of Bomi attracted both financial and strategic buyers, but ArchiMed and management decided that the best fit would be with UPS.

    “We had best-in-class growth and development support from ArchiMed,” says Bomi Chief Executive Marco Ruini. “ArchiMed helped us source, negotiate and close 15 acquisitions over three years, crucially strengthening our business in both Europe and the Americas and expanding our capabilities. In three years, our organic growth moved from high single digit (+6% p.a.) to high double digit (+18% p.a.).” Ruini and his management team will remain in place following the transaction.

    Bomi, headquartered in Spino d’Adda, Italy, was founded in 1985 by Ruini’s father Giorgio. Listed on Borsa Italia’s AIM market, Bomi was taken private by ArchiMed in 2019 and was MED Platform I’s first acquisition. Marco Ruini massively reinvested alongside ArchiMed, with other managers also taking stakes. ArchiMed and management more than doubled revenues at Bomi over three years to some €300 million in 2022.

    MED Platform I and its successor fund MED Platfom II - currently being raised - partner with growth companies in the European and North American mid-cap healthcare sectors, buying majority stakes for €50 million to €1 billion in association with existing owners and managers. The MED Platform funds provide companies with the strategic, tactical and financial resources they need to broaden product lines and expand into new regions, organically and through acquisitions.

    MED Platform II has raised a substantial, but undisclosed amount since launching fundraising in January, which makes it one of the largest Healthcare Buyout funds at a global level. It has an investor re-up rate of almost 100 percent, with the typical commitment larger than the average commitment to MED Platform I. MED Platform II will target 10 to 12 platform investments versus the seven MED Platform I targeted. MED Platform II has attracted a wide-range of institutional and family office investors, with respectively 50 percent, 40 percent and 10 percent coming from Europe, North America and the Asia-Pacific region. In July, MED Platform II made its first acquisition, a $1.1 billion take-private purchase of Nasdaq-listed Natus, a global leader in neurodiagnostic devices. One further platform investment is likely for MED Platform II by the end of year.

    About ArchiMed - www.archimed.group - With offices in the US and Europe, ArchiMed is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ArchiMed to serve as both a strategic and financial partner to North American and European healthcare businesses. Prioritized areas of focus include Biopharmaceutical Products & Services, Life Science Tools, Medical Devices & Technologies, Diagnostics, Health Technologies & Software and Consumer Health. ArchiMed helps partners internationalize, acquire, innovate and expand their products and services. Over the last twenty years, ArchiMed’s leadership team has directly managed and invested in over eighty small- to large-size healthcare companies globally, representing over €50 billion of combined value. ArchiMed manages more than €5 billion across its various funds. Since inception, ArchiMed has been a committed Impact investor, both directly and through its Eurêka Foundation.

    Contacts - France: Stéphanie du Ché, stephanie.duche@archimed.group, +33 (0)6 16 36 11 08;

    International: David Lanchner, dlanchner@lanchner.com, +33 (0)6 33 43 50 76

    Advisors: Morgan Stanley International Inc. acted as exclusive financial advisors to the transaction. Latham & Watkins acted for ArchiMed in the sale. Management advisors were Simmons & Simmons.

    Morgan Stanley & Co. International plc (“Morgan Stanley”), which is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Bomi Group and no one else in connection with the transaction. In connection with such matters, Morgan Stanley, its affiliates and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to anyone other than Bomi Group for providing the protections afforded to clients of Morgan Stanley nor for providing advice in connection with the transaction, the contents of this announcement or any matter referred to herein.

    More
  • 2022/07/21 | ArchiMed acquires Nasdaq-listed Natus Medical Incorporated in $1.1 billion take-private deal

    Natus, a global leader in neurodiagnostic devices, is the first purchase of ArchiMed’s MED Platform II, which began fundraising in January.

    ArchiMed has completed its acquisition of Natus Medical Incorporated (NTUS; NASDAQ) in a $1.1 billion take-private deal. Natus shareholders will receive $33.50 in cash, without interest, for each share of Natus common stock, or a 29 percent premium over the Company’s common stock closing price on April 17, 2022, the day before the public announcement of the parties' entry into definitive agreement. The ArchiMed fund acquiring Natus is MED Platform II, which began fundraising in January.

    Founded in 1987 and headquartered in Middleton, Wisconsin, Natus is a leading global designer, manufacturer and distributor of medical devices for the screening, diagnosis and treatment of disorders affecting the brain, central nervous / peripheral nervous systems, and sensory systems. Natus, with subsidiaries in Canada, Denmark, the UK, Germany, France, Spain, Australia and New Zealand, sells 25 product lines throughout the world, which are used for conditions such as epilepsy, sleep disorders, sensory disorders, neuromuscular diseases and neuro monitoring during medical procedures. Natus employs nearly 1,400 people globally and has engaged in more than 20 revenue-expanding acquisitions since 2004.

    “ArchiMed’s mix of operational, medical, scientific and financial expertise will help us continue our mission to serve our customers as we further integrate, internationalize and grow our business,” says Thomas J. Sullivan, Chief Executive Officer of Natus. “Together with management, we’ll significantly expand the reach and breadth of Natus’ market leading products, reinforce and focus research and development, and pursue acquisitions of complementary businesses,” says ArchiMed Partner Justin Bateman. “Natus is an exciting growth platform with tremendous potential to positively impact patient lives around the world.”

    Natus is the first purchase of ArchiMed’s mid-market buy-and-build fund, MED Platform II (MP II), a successor to the fully invested MED Platform I (MP I). MP I closed on €1 billion in 2020 - at the time, a record for a European-based private equity healthcare fund. It’s currently valued at two times its cost of investment, making it a top decile performer for buyout funds launched in 2019, according to Preqin data. The MED Platform funds partner with growth companies in the European and North American mid-cap healthcare sectors, buying majority stakes for €50 million to €1 billion in association with existing owners and managers. The MED Platform funds provide companies with the strategic, tactical and financial resources they need to broaden product lines and expand into new regions, organically and through acquisitions.

    “We’re aiming to do one or two more platform transactions for MP II before the end of this year, deploying about 25 percent of the fund in six months,” says ArchiMed founder and Managing Partner, Denis Ribon.

    MED Platform II has raised a substantial, but undisclosed amount since launching fundraising in January and remains open to investment. The fund has an investor re-up rate of almost 100 percent with the typical commitment larger than the average commitment to MP I. MP II will target 10 to 12 platform investments versus the seven MP I targeted. MP II has attracted a wide-range of institutional and family office investors, with 50 percent, 40 percent and 10 percent coming respectively from Europe, North America and the Asia-Pacific region. ArchiMed intends to raise considerable cash for bolt-on acquisitions for Natus, partly through co-investment in the company from MED Platform II fund investors.

    In connection with the transaction, Stifel has served as a financial advisor to Natus, and Davis Polk & Wardwell LLP has served as legal advisor to Natus. Jefferies has served as financial advisor to ArchiMed, and Latham & Watkins LLP has served as legal advisor to ArchiMed.

    About ArchiMed - www.archimed.group - With offices in the US and Europe, ArchiMed is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ArchiMed to serve as both a strategic and financial partner to North American and European healthcare businesses. Prioritized areas of focus include Biopharmaceutical Products & Services, Life Science Tools, Medical Devices & Technologies, Diagnostics, Health Technologies & Software and Consumer Health. ArchiMed helps partners internationalize, acquire, innovate and expand their products and services. Over the last twenty years, ArchiMed’s leadership team has directly managed and invested in over eighty small- to large-size healthcare companies globally, representing over €50 billion of combined value. ArchiMed manages €5 billion across its various funds. Since inception, ArchiMed has been a committed Impact investor, both directly and through its Eurêka Foundation.

    About Natus Medical Incorporated - www.natus.com - Natus delivers innovative and trusted solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems to advance the standard of care and improve patient outcomes and quality of life. The Company offers hardware, advanced software and algorithms, and consumables that provide stimulus, acquire and monitor physiological signals, and capture the body’s response. With sales in over 100 countries, Natus is a leader in neurodiagnostics, pediatric retinal imaging, and infant hearing screening, as well as a leading company in hearing assessment, hearing instrument fitting, balance, and intracranial pressure monitoring.

    Contacts - France: Stéphanie du Ché, stephanie.duche@archimed.group, +33 (0)6 16 36 11 08; International: David Lanchner, dlanchner@lanchner.com, +33 (0)6 33 43 50 76

    More
  • 2022/07/12 | ArchiMed invests in Title21 Health Solutions, a leading US-based healthcare software provider

    Title21 Health Solutions is the only end-to-end software provider for cell & gene therapy labs. Its software digitizes all processes, thereby reducing paperwork, optimizing workflow productivity, improving traceability, regulatory compliance, and overall patient safety.

    ArchiMed reinforces its focus in the healthcare software space by investing in Phoenix, Arizona-based Title21 Health Solutions. The Trans-Atlantic private healthcare specialist is acquiring a majority of Title21. The investment was sourced through a direct contact - initiated by ArchiMed - to founders Lynn Fischer and Kent Kirimli, via ArchiMed’s proprietary MedDiscover® platform. Founders and management of Title 21 will retain a significant minority stake. ArchiMed is making the investment through its MED III fund, which closed on €650 million in August, after only two months of fundraising.

    Founded in 2001 and named after the regulatory code governing the food and drug industries in the United States, Title21 is the world’s largest and most highly specialized provider of paperless electronic services to cell & gene therapy labs. Title21’s clients include globally preeminent hospital and research institutions, including the Mayo Clinic, Memorial Sloan Kettering Cancer Center, Stanford University, Kaiser Permanente, and the University of Pennsylvania Health System. The fast-growing cell & gene therapy industry is transforming the treatment of life-threatening conditions including genetic disorders such as spinal muscular atrophy, as well as diseases caused by vital infection, including COVID-19. McKinsey & Company estimates that only 20 percent of cell & gene therapy labs are currently digitized.

    “ArchiMed stood out from other potential partners,” says Lynn Fischer, CEO of Title21. “They share our sense of urgency when it comes to supporting the commercialization of advanced therapies through efficient, easily traceable and scalable technology. They impressed us with their deep domain expertise and track record in cell and gene therapy and as a global leader in healthcare software investing. We couldn’t have found a better partner with whom to scale.” ArchiMed’s investments in healthcare software include Cardioline, a specialist in remote cardiology testing, and ActiGraph, a developer of wearable, remote technology for drug trials. ArchiMed’s investments in cell & gene therapy include, Polyplus, Clean Biologics and Xpress Biologics.

    “Title21 is clearly the best candidate to accelerate digitization in the cell and gene therapy space, not just in the US, but globally,” says ArchiMed Founding Partner Vincent Guillaumot. “Title21’s technology is the most advanced in the world when it comes to ease-of-use, scalability and breadth of offering. As part of this new partnership, we’ll leverage long-established relationships with US hospital groups, accelerate the group’s research and development and help Title21 expand rapidly in Europe and Asia.”

    ArchiMed can more than double its investment in Title21 to support growth. It’s also appointing three C-Suite executives to the board, Peter Bailey, Brian Smith and Dan Drawbaugh. Both Bailey and Smith are part of ArchiMed’s MedTalents®, a global network of ArchiMed-associated senior healthcare executives who identify, facilitate and advise on deals and counsel portfolio companies. Bailey was the former CEO of LabVantage and currently sits on the Board of Xybion, a prominent laboratory information management software company. Smith, an Operating Partner at ArchiMed, is currently the Chairman and CEO of ArchiMed-owned Ad-Tech, which makes minimally invasive brain electrodes featuring ease of use and connectivity. Drawbaugh is currently CEO of the Steadman Clinic, and formerly CIO at the University of Pittsburgh Medical Center.

    “Specialized software continues to penetrate the healthcare space to optimize workflows. We can leverage both our software knowledge and expertise in cell and gene therapy to support Title21’s next phase of growth,” adds Guillaumot.

    MED III invests in small-cap healthcare sectors in Europe and the Americas, partnering with owners and managers. The fund’s other investments are Cardioline and Corealis Pharma. The latter provides outsourced formulation development and manufacturing of tablets, capsules and granules for preclinical and clinical trials.

    About ArchiMed - www.archimed.group - With offices in the US and Europe, ArchiMed is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ArchiMed to serve as both a strategic and financial partner to North American and European healthcare businesses. Prioritized areas of focus include Biopharmaceutical Products & Services, Life Science Tools, Medical Devices & Technologies, Diagnostics, Health Technologies & Software and Consumer Health. ArchiMed helps partners internationalize, acquire, innovate and expand their products and services. Over the last twenty years, ArchiMed’s leadership team has directly managed and invested in over eighty small- to large-size healthcare companies globally, representing over €50 billion of combined value. ArchiMed manages €5 billion across its various funds. Since inception, ArchiMed has been a committed Impact investor, both directly and through its Eurêka Foundation.

    About Title21 - www.title21.com -Since 2001, Title21 Health Solutions has been dedicated to delivering easy-to-use, flexible and integrated technology to support health sciences organizations achieve compliance, gain efficiencies and ensure high quality, ultimately, to support improvement in patient safety and care. Their sole focus is developing technology to meet the specific needs of healthcare and life sciences firms, resulting in comprehensive solutions that are flexible to evolving business and regulatory requirements. Through the years, their partnerships with industry leaders have steered their innovations to continue to meet the dynamic needs of the markets they serve. As the breadth of Title21’s technology solutions has expanded, their mission and dedication to customers’ success and supporting the improvement of patient care has served as the true north. For the team at Title21 Health Solutions, their passion is to deliver technology that better enables customers to deliver products and services that truly make a difference and enable world class patient care.

    Contacts - France: Stéphanie du Ché, stephanie.duche@archimed.group, +33 (0)6 16 36 11 08;

    International: David Lanchner, dlanchner@lanchner.com, +33 (0)6 33 43 50 76

    More
  • 2022/05/24 | ArchiMed invests in Corealis Pharma, a North American CDMO, through MED III

    The significant recapitalization of the Americas’ leading CDMO for pharmaceutical oral solid dosage formulation and clinical supply manufacturing will accelerate growth, including the build-out of state-of-the-art laboratories and Good Manufacturing Practices-compliant facilities.

    Trans-Atlantic private equity healthcare specialist ArchiMed is the lead investor in an alliance recapitalizing Corealis Pharma. ArchiMed and fellow investor, the Caisse de dépôt et placement de Québec - the second largest pension fund in Canada with C$419 billion under management - are joining forces with founders and management through this recapitalization. The partnership will further expand the high-quality drug development services Corealis offers as a Contract Development and Manufacturing Organization to small and medium-sized biotech and pharma companies. Cutting-edge capabilities and economically efficient outsourced services play a critical role in contemporary drug discovery and development.

    Founded in 2005 and based in Laval, Québec, Canada, Corealis is the market-leading CDMO in the Americas for the formulation and manufacture of solid dosage oral pharmaceuticals – tablets, capsules and granules – during preclinical and clinical pre-commercialization trials. Corealis is the second investment of ArchiMed’s MED III fund, which closed on €650 million in August, after less than two months of fundraising.

    “ArchiMed understood our strategy and offered an attractive investment thesis,” says Yves Roy, President of Corealis. “We turned down several higher offers from prospective suitors - trade and financial. Like us, ArchiMed understands the important potential of this industry and what it takes to get to the next level. As partners we’ll be able to capitalize on market leadership, aggressively expanding scientific strengths in R&D and our best-in-class regulatory-compliant manufacturing processes [such regulatory compliant processes are known as Good Manufacturing Practices or GMP].” Roy and fellow founders Patrick Gosselin and Yves Mouget retain a significant stake in Corealis.

    “With Corealis’ expertise, CDPQ’s clout, and our knowledge of the international healthcare landscape, we’ve got the perfect combination to rapidly scale up in a fast-growing industry,” says ArchiMed Partner Robin Filmer-Wilson. Since 2019, Corealis’ sales registered average annual growth of more than 15 percent, a pace set to rise as drug formulation outsourcing increases in response to inflation and more demanding regulations. The deal was sourced through ArchiMed’s Pharma Services team, aided by ArchiMed’s MedTalents®, a global network of ArchiMed-associated senior healthcare executives who identify, facilitate and advise on deals and counsel portfolio companies.

    MED III invests in small-cap healthcare sectors in Europe and the Americas, partnering with owners and managers. MED III also owns Europe-based Cardioline, which offers sophisticated, remote cardiology testing and diagnostics.

    About ArchiMed - www.archimed.group. With offices in the US and Europe, ArchiMed is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ArchiMed to serve as both a strategic and financial partner to North American and European healthcare businesses. Prioritized areas of focus include biopharmaceutical products & services, life science tools, medical devices & technologies, diagnostics, health technologies & software and consumer health. ArchiMed helps partners internationalize, acquire, innovate and expand their products and services. Over the last twenty years, ArchiMed’s leadership team has directly managed and invested in over eighty small to large-size healthcare companies globally, representing over €50 billion of combined value. ArchiMed manages €5 billion across its various funds. Since inception, ArchiMed has been a committed Impact investor, both directly and through its Eurêka Foundation.

    ArchiMed Press Contacts

    France: Stéphanie du Ché, stephanie.duche@archimed.group, +33 (0)6 16 36 11 08; International: David Lanchner, dlanchner@lanchner.com, +33 (0)6 33 43 50 76

    ArchiMed Advisors

    Finance - Mazars

    Corporate Finance - William Blair

    Legal - Cassels

    Seller Advisors

    Corporate Finance - Fairmount Partners

    Legal - Stikeman Elliott

    More
  • 2022/05/09 | ArchiMed’s MED II fund earns a 6x return on its first exit

    The purchase of point-of-care specialist EUROLyser by Antech Diagnostics brings EUROLyser’s innovative technology and expansion opportunities to Europe and beyond.

    Trans-Atlantic private equity healthcare specialist ArchiMed announces the sale of point-of-care diagnostics specialist EUROLyser to Antech Diagnostics, part of Mars Veterinary Health. This first exit for ArchiMed’s MED II - the fund raised €315 million in 2017 - earns six times the money invested in EUROLyser, or an 80 percent annualized return. EUROLyser, purchased three years ago - with company management holding a significant minority position - also hands more than half of the capital raised for MED II back to investors and marks the fund as a top-decile performer among all global buyout funds for its vintage year, according to Preqin data.

    Founded in 2005, Salzburg, Austria-based EUROLyser designs and engineers patented point-of-care testing equipment and kits, diagnosing a wide range of conditions in animals and humans. Point-of-care testing is done at the time of consultation, leading to the immediate availability of results and more timely, informed decisions concerning treatment.

    Working in partnership with management - including company founders - ArchiMed increased EUROLyser’s profits more than two-fold, boosting average annual sales growth to more than 25% during its three-year holding period - up from the high single-digits in the years prior to its purchase. This was achieved through various strategic actions, including investing in efficient technologies (such as remote access to in-the-field analyzers); negotiating a range of commercial partnerships with veterinary care groups; additional sales expansion in the US; and hires to strengthen regulatory affairs and research and development. Two board members, both in vitro diagnostics experts who played key roles pursuing growth, Dr. Dirk Ehlers and Michael Williams, were recruited through ArchiMed’s MedTalents® (a global network of ArchiMed-associated senior healthcare executives who identify, facilitate and advise on deals and counsel portfolio companies).

    “ArchiMed knew exactly what we needed to not let opportunities slip by,” says Michael Gruber, co-founder and CEO of EUROLyser. “The partnership with Antech is an example of this.” “We’re pleased to have helped EUROLyser reach its next stage of growth,” says ArchiMed Managing Partner Vincent Guillaumot.

    Adds Lonnie Shoff, President of Antech, “We believe EUROLyser will help us make a better world for pets due to its global footprint, unique products and the expertise of its R&D and management teams.”

    Following the sale of EUROLyser, the fully invested MED II owns ten companies, including two other diagnostics specialists: Diesse, a developer of both in vitro systems for detecting autoimmune and infectious diseases (including Covid-19), and hematology systems for diagnosing inflammation; and ZytoMax, a developer, manufacturer and distributor of precision medicine cancer tests.

    About ArchiMed - www.archimed.group With offices in the US and Europe, ArchiMed is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ArchiMed to serve as both a strategic and financial partner to North American and European healthcare businesses. Prioritized areas of focus include biopharmaceutical products & services, life science tools, medical devices & technologies, diagnostics, healthtech and consumer health. ArchiMed helps partners internationalize, acquire, innovate and expand their products and services. Over the last twenty years, ArchiMed’s leadership team has directly managed and invested in over eighty small to large-size healthcare companies globally, representing over €50 billion of combined value. ArchiMed manages €5 billion across its various funds. Since inception, ArchiMed has been a committed Impact investor, both directly and through its Eurêka Foundation.

    Contacts:

    France: Stéphanie du Ché, stephanie.duche@archimed.group, +33 (0)6 16 36 11 08

    International: David Lanchner, dlanchner@lanchner.com, +33 (0)6 33 43 50 76

    More
  • 2022/02/02 | ArchiMed sells health ingredients developer Fytexia to Associated British Foods

    Sale earns a 4x return - Fytexia’s soaring top and bottom-line growth is set to continue in new partnership with Associated British Foods. 

    Trans-Atlantic private equity healthcare specialist ArchiMed announces the sale of health ingredients developer Fytexia to diversified food, ingredients and retail group, Associated British Foods, a FTSE 100 company. The transaction - which sees Fytexia join the ABF Ingredients division - earns ArchiMed’s inaugural MED I fund four times its investment. Following Fytexia’s sale, MED I retains its rank as the best performing buyout fund in the world across all sectors for the 2014 vintage, according to Preqin data. MED I has returned four and a half times invested capital to limited partners to date. Its total return - including four realized and five remaining investments - is seven times invested capital.

    Working hand-in-hand with management since buying Fytexia in 2016, ArchiMed has built it into a category leader in botanic and propolis-based polyphenols through senior level recruitment (commercial, board, finance, production, R&D), multiplication of clinical studies, product diversification, North American sales expansion and targeted acquisition. In 2021, using its global MedTalents® network (ArchiMed-associated senior healthcare professionals who identify, facilitate and advise on deals and counsel portfolio companies), ArchiMed sourced and executed Fytexia’s transformational acquisition of Milan, Italy-based B Natural - a leader in propolis-based polyphenols - boosting sales some 40 percent.

    Under ArchiMed’s ownership, total annual Fytexia sales growth has risen from the single digits to close to 30 percent for the past four years. Profits have risen four-fold over the same period.

    “Our partnership with Fytexia is an example of the whole being greater than sum of the parts,” says ArchiMed partner, Robin Filmer-Wilson.  “We put our skills in healthcare business development and M&A at the service of talented management teams looking to accelerate growth into the long-term. With their expertise, global reach and scale, ABF is the perfect relay partner for Fytexia’s continued expansion in this burgeoning sector.”

    Businesses previously sold by ArchiMed’s MED I include healthcare ingredients group HIS, for an annualized return of over 400 percent; dental operator Primo, for three times investment; and gene and cell therapy technology specialist Polyplus-transfection for almost 70 times investment.

    About ArchiMed - www.archimed.group  

    With offices in the US and Europe, ArchiMed is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ArchiMed to serve as both a strategic and financial partner to European and North American small and middle-market businesses. Prioritized areas of focus include biopharmaceutical products & services, life science tools, medical devices & technologies, diagnostics, healthcare IT and consumer health. ArchiMed helps partners internationalize, acquire, innovate and expand their products and services. Over the last twenty years, ArchiMed’s leadership team has directly managed and invested in over eighty small to large-size healthcare companies globally, representing over €50 billion of combined value. ArchiMed manages over €4 billion ($4.8 billion) in healthcare assets across its various funds. Since inception, ArchiMed has been a committed Impact investor, both directly and through its Eurêka Foundation.

    Contacts

    France: Stéphanie du Ché, stephanie.duche@archimed.group, +33 (0)6 16 36 11 08

    International: David Lanchner, dlanchner@lanchner.com, +33 (0)6 33 43 50 76

    More